Lymphoma Drug Outperforms Remdesivir Against Covid Virus
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
A chemotherapy medication originally developed to treat lymphoma has outperformed the popular remdesivir drug against SARS-CoV-2 in lab settings, and could potentially be repurposed to treat Covid-19, say researchers.

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate drug is a promising candidate for Covid-19 patients. This approach identified four promising drugs, which were then tested against SARS-CoV-2 in lab experiments. Two of the drugs, pralatrexate and azithromycin, successfully inhibited replication of the virus.

The team screened 1,906 existing drugs for their potential ability to inhibit replication of SARS-CoV-2 by targeting a viral protein called RNA-dependent RNA polymerase (RdRP). The findings suggest that pralatrexate could potentially be repurposed to treat Covid-19.

"This chemotherapy drug can prompt significant side effects and is used for people with terminal lymphoma, so immediate use for Covid-19 patients is not guaranteed. Still, the findings support the use of the new screening strategy to identify drugs that could be repurposed," the researchers noted.

Source:
https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1008489
Dr. T●●●●z H●●●●●●i and 1 others like this
Like
Comment
Share